top of page

Research Roundup: May 2, 2023

Best of cannabinoid science this week...

In a case report of a clinically high risk mental state individual being treated with 600 milligrams of CBD per day for a month, their clinical improvements seem to be because of better cerebral glucose utilization, possibly via the PPAR nuclear receptors Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state

In a mouse model of the neuropathic pain of chemotherapy, CBD combined well with mitragynine (the active ingredient of kratom) to lower several measures of pain & touch sensitivity

Cannabidiol And Mitragynine Exhibit Differential Interactive Effects In The Attenuation Of Paclitaxel-Induced Mechanical Allodynia, Acute Antinociception, And Schedule-Controlled Responding In Mice

In a mouse model of the neuropathic pain of chemotherapy, CBD lowered the pain via activation of the endocannabinoid system & the Toll-like receptors in the spinal cord Cannabidiol prevents chemotherapy-induced neuropathic pain by modulating spinal TLR4 via endocannabinoid system activation

In mice exposed to the pollutant perfluorooctanesulfonic acid, CBD protected their heart cells from the damage of oxidative stress as well as bringing balance to the energy metabolism disorder caused by damage to the mitochondria (energy center of the cell) Cannabidiol Alleviates Perfluorooctanesulfonic Acid-Induced Cardiomyocyte Apoptosis by Maintaining Mitochondrial Dynamic Balance and Energy Metabolic Homeostasis

A general review article on why targeting the PPAR nuclear receptors (which turn genes on & off) is important for treating neuropsychiatric disease

The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders

On the endocannabinoid system & breathing The endocannabinoid system and breathing


bottom of page